首页> 外文期刊>Korean journal of radiology : >Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas
【24h】

Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas

机译:大型孤立性或多结节性肝细胞癌患者经动脉化疗栓塞加微波消融与单独经动脉化疗栓塞的疗效和预后因素的比较

获取原文
           

摘要

Objective To evaluate the efficacy and prognostic factors associated with transcatheter arterial chemoembolization (TACE) combined with microwave ablation (MWA) versus TACE alone for a large solitary or multinodular hepatocellular carcinomas (HCCs). Materials and Methods This retrospective study involved 258 patients with a large solitary or multinodular HCCs (not more than 10 tumors) who underwent TACE + MWA (n = 92) or TACE alone (n = 166) between July 2011 and April 2015. Local tumor control, survival outcomes, and complications were compared between the two groups. Prognostic factors for time to progression (TTP) and overall survival (OS) were evaluated by univariate and multivariate analyses. Results The median duration of follow-up was 21.2 months (range, 4–45 months). The median TTP and OS were 12.5 months and 26.6 months, respectively, for the TACE + MWA group and 6.7 months and 17.1 months, respectively, for the TACE group ( p Conclusion TACE + MWA appears to have more advantages compared to TACE in prolonging OS, with a satisfactory TTP, for inpatients with solitary large or multinodular HCCs. Treatment method, tumor size, and tumor number are significant prognostic factors for TTP and OS. Further randomized, multi-center, prospective trials are required to confirm the findings of this study.
机译:目的评估经导管动脉化疗栓塞(TACE)联合微波消融(MWA)与单独TACE联合治疗大型孤立性或多结节性肝细胞癌(HCC)的疗效和预后因素。资料和方法这项回顾性研究涉及258例患有大孤立性或多结节性HCC(不超过10个肿瘤)的患者,这些患者在2011年7月至2015年4月间接受了TACE + MWA(n = 92)或单独进行TACE(n = 166)。比较两组的控制,生存结果和并发症。通过单因素和多因素分析评估了进展时间(TTP)和总生存期(OS)的预后因素。结果随访的中位时间为21.2个月(范围4–45个月)。 TACE + MWA组的中位TTP和OS分别为12.5个月和26.6个月,TACE组的中位TTP和OS分别为6.7个月和17.1个月(p结论与TACE相比,TACE + MWA在延长OS方面似乎具有更多优势TTP令人满意,对于单发大或多结节肝癌的住院患者,治疗方法,肿瘤大小和肿瘤数目是TTP和OS的重要预后因素,还需要进一步的随机,多中心,前瞻性试验来证实这一发现。研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号